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Targeting growth-regulatory pathways is a promising approach in cancer treatment. A prerequisite to the development of such
therapies is characterisation of tumour growth regulation in the particular tumour cell type of interest. In order to gain insight into
molecular mechanisms underlying proliferative responses in neuroendocrine (NE) gastrointestinal (GI) tumours, we investigated gene
expression in human carcinoid BON cells after exposure to gastrin, hepatocyte growth factor (HGF), pituitary adenylate cyclase-
activating polypeptide or epidermal growth factor. We particularly focused on gastrin- and HGF-induced gene expression, and
identified 95 gastrin- and 101 HGF-responsive genes. The majority of these genes are known mediators of processes central in
tumour biology, and a number of them have been associated with poor prognosis and metastasis in cancer patients. Furthermore, we
identified 12 genes that were regulated by all four factors, indicating that they may be universally regulated during NE GI tumour cell
proliferation. Our findings provide useful hypotheses for further studies aimed to search for new therapeutic targets as well as tumour
markers in NE GI tumours.
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Carcinoids are the most common type of neuroendocrine (NE)
tumours found in the gastrointestinal (GI) system (O ¨berg, 2000;
Modlin et al, 2003). Although rare, with an incidence of
approximately 1–2/100000 per year (O ¨berg, 2000; Modlin et al,
2003), the prevalence is high because of their usually well-
differentiated nature and relatively slow growth rate. However,
some patients have highly aggressive tumours leading to early
death, while many of those living for several years have debilitating
symptoms due to hypersecretion of biogenic amines and
hormones. Surgery is the only potentially curative treatment, but
since distant metastasis or regional disease are often present at the
time of diagnosis, cure is most often not possible (Modlin et al,
2003). Thus, new therapeutic options are needed. Targeting key
growth-regulatory pathways is a promising approach in cancer
treatment (Behe and Behr, 2002; Yee, 2002; Sridhar et al, 2003;
Ranson, 2004; Jiang et al, 2005), and requires a thorough
knowledge of molecular mechanisms involved in growth regula-
tion of various tumour cell types.
The amidated form of the peptide hormone gastrin is a well-
known regulator of gastric acid secretion and GI mucosal growth
and organisation (Waldum et al, 1995; Dockray et al, 2001, 2005).
In addition, there is abundant evidence to suggest that gastrin may
play an important role in tumour biology, as it is shown to regulate
tumour cell growth (Dockray et al, 2001, 2005), and stimulate
tumour cell invasion (Kucharczak et al, 2001) as well. Further-
more, hypergastrinaemia is associated with the occurrence of
gastric enterochromaffin-like (ECL) cell carcinoid tumours (Wal-
dum et al, 1995; Dockray et al, 2001, 2005; Richards et al, 2004)
and with an increased risk of gastric and colorectal carcinoma
(Dockray et al, 2001), indicating a role also in carcinogenesis. The
biological actions of amidated gastrin are exerted through high-
affinity binding to the gastrin/cholecystokinin B (CCK2) receptor
(Denyer et al, 1994). This receptor has been shown to be
coexpressed with gastrin in several GI tumour cell lines (Watson
et al, 1998) and in human gastric carcinoids (Smith et al, 1998),
indicating the existence of an autocrine gastrin growth-stimulatory
loop. Interestingly, progress is being made in the development of
CCK2 receptor targeting peptides for staging and therapy of
human tumours (over)expressing this receptor (Behe and Behr,
2002).
Hepatocyte growth factor (HGF)/scatter factor was originally
described as a factor promoting growth and scattering of multiple
myeloma cells (Børset et al, 1996; Maulik et al, 2002). It is now
clear that HGF exerts pleiotropic effects in a wide variety of
tumour cells, where binding of HGF to its tyrosine kinase receptor
c-Met promotes scattering, proliferation, angiogenesis, enhanced
cell motility, invasion and metastasis (Maulik et al, 2002).
However, its role in NE GI tumour cell biology is not yet defined.
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adenylate cyclase-activating polypeptide (PACAP), which is known
to regulate proliferation, differentiation and apoptosis in a number
of malignant cells (Sherwood et al, 2000). However, PACAP and its
various receptor forms have been found expressed in human NE
tumours such as pheochromocytomas and neuroblastomas (Reubi
et al, 2000; Sherwood et al, 2000), and PACAP has been found to
modulate rat gastric ECL cell proliferation (La ¨uffer et al, 1999),
indicating a possible role of PACAP in NE GI tumour cell biology
as well.
Targeting the epidermal growth factor (EGF) receptor has
emerged as a promising approach in the treatment of various types
of cancers (Sridhar et al, 2003; Ranson, 2004). The EGF receptor is
found (over)expressed in various human NE tumours (Nilsson
et al, 1995; Wulbrand et al, 1998; Peghini et al, 2002), including GI
carcinoids. More recently, the EGFR tyrosine kinase inhibitor
gefitinib has been shown to inhibit growth of various NE GI
tumour cells, including human carcinoid BON cells (Ho ¨pfner et al,
2003). The establishment of the BON cell line has been a major
contribution to the study of growth regulation of NE GI tumours
(Evers et al, 1991). Both serotonin (Ishizuka et al, 1992) and
insulin-like growth factor (IGF)-1 (von Wichert et al, 2000) have
been shown to act as autocrine regulators of growth of BON cells,
while nerve growth factor (Bold et al, 1995) and basic fibroblast
growth factor (FGF) stimulate growth in a nonautocrine manner
(Townsend et al, 1993).
Various growth factor receptors are attractive targets for novel
treatment approaches in NE GI tumour disease. In the present
study, we employ transcript profiling to examine molecular
mechanisms underlying proliferative responses in BON carcinoid
tumour cells after exposure to gastrin, HGF, EGF and PACAP. By
this approach, we identify a number of genes not previously
known to be regulated by these growth factors and discuss the
relevance of some of them as candidates for further studies in the
search for new therapeutic targets in NE GI tumours.
MATERIALS AND METHODS
Cell lines
Human pancreatic carcinoid BON cells (Evers et al, 1991) were a
generous gift from Professor Kjell O ¨berg, Department of Medical
Sciences, Uppsala University Hospital, Uppsala, Sweden, and were
grown in a 1:1 composition of Dulbecco’s modified Eagle’s
medium (Gibco-BRL, Life Technologies, Paisley, Scotland) and
RPMI 1640 medium (Gibco), containing 2gl
 1 glucose, 10Uml
 1
penicillin/streptomycin (Gibco) and 10% heat-inactivated foetal
calf serum (FCS) (Biological Industries, Beit Haemek, Israel). The
colon carcinoma LoVo cell line was obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA), and grown
in RPMI 1640 medium containing 10% FCS, 2mML -glutamine,
4.5gl
 1 glucose and 10Uml
 1 penicillin/streptomycin.
Reagents
Heptadecapeptide-amidated gastrin and forskolin were obtained
from Sigma (St Louis, MO, USA). Hepatocyte growth factor was a
kind gift from Professor Magne Børset, Department of Cancer
Research and Molecular Medicine, Norwegian University of
Science and Technology, Trondheim, Norway. Recombinant EGF
was purchased from Biomedical Technologies (Stoughton, MA,
USA), and PACAP-38 from Bachem (Bobendorf, Switzerland).
Proliferation
Proliferation rate was determined by measuring DNA synthesis
using the Cell proliferation ELISA BrdU (5-bromo-20-deoxyur-
idine) kit (Roche Applied Science, Mannheim, Germany). A total
of 2 or 4 10
3 BON cells were seeded out in 96-well microtitre
plates in serum-containing medium. After 24h, the cells were
washed once with serum-free medium and then treated with
various growth factors for 24h. Incorporation of BrdU was
measured as described previously (Hofsli et al, 2002).
Radioimmunoassays (RIAs)
For detection of gastrin, BON cells were grown to confluence in
six-well tissue culture plates and serum starved for 24h in a
volume of 1.2ml, before the medium was collected, and cell lysates
prepared by lysis in 400ml distilled water. Samples were kept
frozen at  801C before amidated gastrin was measured using an
RIA method as described previously (Kleveland et al, 1985).
Detection of c-Met, CCK2 and PAC1 receptor mRNA
Total RNA (2mg) from BON cells was reverse transcribed (421C/
60min) in a volume of 20ml using MulV reverse transcriptase (RT)
(Roche Applied Science). A measure of 2ml of a 1:3 dilution of
cDNA was then amplified in a 20ml polymerase chain reaction
(PCR) mix (Roche Applied Science) containing a final concentra-
tion of 1.6mM MgCl2, 500nM of each primer, 1U of AmpliTaq Gold
and 300mM dNTP. PCR amplifications were run for 36 cycles with
annealing temperature of 581C (c-Met), 641C (CCK2) and 561C
(PAC1) receptor, respectively. The following primers were used (-S
designates sense and -AS antisense primer): c-Met-S – 50-
TGGGAATCTGCCTGCGAA-30; c-Met-AS, 50-CCAGAGGAC-
GACGCCAAA-30 (Børset et al, 1996); CCK2-S – 50-AAC ACA
AAC CAC AAC TGA-30; CCK2-AS – 50-AGG TCA AAC TAG GAG
CAT-30 (GenBank accession no. reference sequence; NM 176875);
and PAC1-R-S – 50-CCC TGA GCT CTT CCG AAT-30; PAC1-R-AS –
50-CCC ACA GGC ATC AAA GTA-30 (NM 001118).
Treatment of cells and isolation of RNA
For determination of growth factor-induced gene expression, BON
cells were cultured in 75cm
2 culture flasks for 72h until confluence
was reached. After serum starvation for 24h, cells were exposed to
either gastrin (10nM), HGF (100ngml
 1), EGF (100ngml
 1)o r
PACAP (10nM) for 6h. Untreated cells served as controls. RNA
was isolated using the RNeasy Midi kit (Qiagen, Valencia, CA,
USA), according to the manufacturer’s instructions. RNA was
examined for degradation by agarose gel electrophoresis with
evaluation of the 18S and 28S ribosomal RNA bands and by use of
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA). RNA concentration was assessed spectrophotometrically.
The samples were kept frozen at  801C until further processing.
Microarray hybridisation
Arrays were manufactured by the Norwegian Microarray Con-
sortium (www.mikromatrise.no/) using cDNA probes representing
2503 sequence-verified human genes (Research Genetics, Hunts-
ville, AL, USA), including 1500 genes defined at that time in the
NCI Oncochip selection. Of the 2503 genes, 2501 were printed in
duplicates and two in quadruplicates. Additional information of
cDNA clone preparation and printing are given in Nørsett et al
(2004) and Yadetie et al (2003). Total RNA (1mg) from growth
factor-treated and from untreated control cells (at time point zero)
was reverse transcribed and labelled with Cy5- and Cy3-attached
dendrimer, respectively, using the Genisphere 3DNA dendrimer kit
(Genisphere, Montvale, NJ, USA) as described in the manufac-
turer’s protocol and previously by us (Nørsett et al, 2004; Yadetie
et al, 2003). Hybridised arrays were scanned separately at two
wavelengths (532 and 633nm).
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Image analysis was carried out with the Microarray Suite software
version 2.1 (Scanalytics, Fairfax, VA, USA). All subsequent
statistical analyses were performed using the statistical package
R, (R Development Core Team, 2004). Preprocessing consisted of
automatic removal of weak spots and removal of systematic errors
by normalisation. Spots with background-corrected spot intensity
lower than the local background intensity in at least one channel
were excluded from the analysis. Intensity-based normalisation
was performed using locally weighted scatterplot smoothing (Yang
et al, 2002).
Differentially regulated genes for each of the four treatments
(gastrin, HGF, EGF and PACAP) were identified in a two-step
procedure for each gene separately. First, a linear mixed effects
model was fitted to the normalised log ratios of each gene, with the
microarray slide as a random effect to take into account the
correlation between multiple spots of each gene on the same slide.
The nlme-software presented in Pinheiro and Bates (2000) was
used to fit the model, and to produce a P-value for each gene based
on a t-test in the fitted linear mixed effects model. In this first step,
genes with P-values below 0.05 were selected as potentially
interesting genes. It is, however, well known that gene-specific
variances estimated from small sample sizes are unstable. To avoid
that small estimated variances dominate genes with small
estimated effects, a ratio cutoff of 0.8 and 1.25 was used on the
selected genes.
To check the robustness of our analyses, we also calculated P-
values based on a moderated t-test, as implemented in the Limma
R package of Smyth (2004). The moderated t-test is based on
empirical Bayes analysis, and is equivalent to shrinkage (or
expansion) of the estimated sample variances towards a pooled
estimate, resulting in more stable inference when the number of
microarray experiments is small. A similar effect was achieved
using the ratio cutoff in our two-step procedure. Duplicate spotted
genes were averaged before the moderated t-tests were performed.
The results to be presented are based on the two-step procedure,
but in addition the maximum P- and q-values (Storey and
Tibshirani, 2003) from the moderated t-tests on the selected gene
sets are reported. The q-value of a gene can be interpreted as the
minimum false discovery rate that can be attained when calling a
given gene significantly differentially expressed. We have calcu-
lated a conservative version of the q-values, using 1 as the
estimated proportion of genes truly not differentially expressed.
Quantitative RT–PCR
Verification of the microarray data was performed by quantitative
RT–PCR analysis using the Smart Cycler (Cepheid, Sunnyvale, CA,
USA). First, total RNA in a final concentration of 0.1mgml
 1 was
reverse transcribed (481C/60min) using 1Uml
 1 of Euroscript RT
(Reverse Transcription Core Kit, Eurogentec, Seraing, Belgium).
Undiluted cDNA (2ml) were then amplified for 30–40 cycles in a
25ml PCR mix (qPCRt Core Kit for Sybrt Green I-No ROX)
(Eurogentec) containing a final concentration of 2.5mM MgCl2 and
300nM of each primer. Each cycle consisted of denaturing for 15s
at 951C, annealing for 15s at 551C and polymerisation for 30s at
721. The Ct value, defined as the number of cycles required to
produce a detectable product above background fluorescence, was
measured for each sample, and arbitrary units were calculated
using a standard curve, which was run for each individual PCR
analysis. The standard curves consisted of serial dilutions of cDNA
of a sample or a control containing the highest amount of the
specific gene analysed. A negative control without the cDNA
template was run with every PCR assay, and contamination by
genomic DNA was ruled out by performing PCR analysis on
template where RT had been omitted in the RT reactions.
Glyceraldehyde-3-phosphate dehydrogenase RT–PCR were run
in parallel as control to monitor RNA integrity and to be used for
normalisation. Specificity of each primer pair was confirmed by
melting curve analysis and agarose gel electrophoresis. Table 1
shows the primer sequences and expected sizes of the PCR
products.
RESULTS
Gastrin-induced proliferation
Since gastrin appears to be an important growth factor of various
tumour cell types (Dockray et al, 2001, 2005; Richards et al, 2004),
and since some gastric carcinoids have been shown to express the
CCK2 receptor (Smith et al, 1998), we examined whether gastrin
could affect growth of carcinoid tumour cells as well. As shown in
Figure 1A, gastrin induced proliferation of BON cells in a dose-
dependent manner. A maximum 1.7-fold increase was seen, which
was comparable to that induced by FCS (1.4). To explore a possible
role of gastrin as an autocrine growth factor of BON cells, we
measured the gastrin protein levels in cell lysates and in
conditioned medium. Our finding that BON cells do not produce
gastrin themselves (detection limit in our assay is 5pgml
 1)i si n
agreement with immunohistochemical findings of Evers et al
(1991).
Since there have been conflicting results as to the question
whether BON cells express the CCK2 receptor (Evers et al, 1991;
Kim et al, 1997), we analysed for its mRNA by RT–PCR analysis.
The results clearly demonstrate that BON cells express CCK2
receptor mRNA (Figure 2). Although this finding does not
necessarily mean that the CCK2 receptor protein is being
expressed in BON cells, it indicates that the observed growth-
stimulatory effect of gastrin is mediated via this receptor.
Together, our findings support the view that gastrin may act as a
regulator of carcinoid tumour growth (Smith et al, 1998; Behe and
Behr, 2002).
HGF-, EGF- and PACAP-induced proliferation
In order to further explore growth regulation of human NE GI
tumour cells, we tested a panel of other factors known to affect cell
growth of other tumour cell types. We here report the novel
findings that HGF, EGF and PACAP all stimulate proliferation of
carcinoid BON cells (Figure 1B–D). A maximum 2.4-fold increase
in proliferation was seen after stimulation with 50ngml
 1 of HGF.
By RT–PCR analysis, BON cells were shown to express mRNA of
the HGF receptor (c-Met) (Figure 2), indicating a possible role of
HGF in controlling growth of carcinoids. This is perhaps not
surprising, as an aberrant c-Met signalling, either caused by
overexpression/mutation of c-Met or by coexpression of c-Met and
HGF, has been found in a variety of other malignancies (Maulik
et al, 2002). Only two studies have so far investigated c-Met
expression in NE GI tumours. Wulbrand et al (1998) found the c-
Met mRNA expression frequencies to vary considerably, with the
highest found in gastrinomas (33%) and the lowest (11%) in small
intestine carcinoid tumours. In a gastrinoma study (Peghini et al,
2002), universal expression of c-Met mRNA was demonstrated in
all 22 tumours investigated. Compared to normal pancreas, only a
minority of the tumours (14%) showed slight overexpression of c-
Met. Unlike findings in other tumour types (Maulik et al, 2002), c-
Met overexpression in these gastrinomas were not correlated with
a more aggressive tumour behaviour. In conclusion, the present
study indicates that the BON cell line could serve as a valuable
experimental model to study molecular mechanisms involved in
HGF-mediated responses in NE tumour cells.
Our finding that EGF stimulates growth of BON cells (Figure 1C)
was somewhat surprising, since others did not find this effect in
BON (Townsend et al, 1993). A maximum 1.6-fold increase was
Growth-responsive genes in neuroendocrine tumour cells
E Hofsli et al
1508
British Journal of Cancer (2005) 92(8), 1506–1516 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sseen using either 50 or 100ngml
 1 EGF. The discrepancy of results
may relate to the fact that we used a more sensitive method for
measurement of proliferation, or to phenothypic changes that may
have occurred during cultivating of cells for years in vitro. Western
blot analysis revealed a constitutive expression of phosphorylated
(activated) EGF receptor in BON cells (data not shown), indicative
of an aberrant EGF signalling in these cells. Recently, EGFR
expression has in fact been demonstrated in BON cells (Ho ¨pfner
et al, 2003), but BON cells were not found to express the EGFR
mutation EGFRvIII, which is often observed in non-NE tumours.
Also, PACAP was found to enhance DNA synthesis in BON cells
(Figure 1D). Both the concentration of 0.1 and 1nM PACAP
increased the proliferation by a factor of 2.2. Only a weak increase
was observed with 10nM PACAP. By RT–PCR analysis, BON cells
were found to express mRNA of the PACAP selective receptor
PAC1, but not VIP/PACAP receptors (data not shown). This is in
agreement with earlier findings showing that tumours located in
the NE system appear to express predominantly the PAC1 receptor
(Reubi et al, 2000). Furthermore, it is consistent with findings in
this study showing that PACAP in the range of 0.1–10nM induces
proliferation of BON cells, and with those in a previous study from
our group showing that PACAP at the same concentrations
induces histamine release from ECL cells known to only possess
PAC1 and not VIP/PACAP receptors (Sandvik et al, 2001). No
previous studies have investigated the expression of PACAP and
its receptors in carcinoids. Our assumption that PACAP could act
as an important growth regulator of NE GI tumours is supported
by the fact that PACAP has been found to modulate rat gastric
ECL cell proliferation, a cell type which during malignant
transformation gives origin to gastric carcinoid tumours (La ¨uffer
et al, 1999).
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Figure 1 Growth factor-induced proliferation of BON cells. BON cells were stimulated for 24h with gastrin (A), HGF (B), EGF (C) or PACAP (D), with
quadriplicate parallels per condition, and proliferation measured as BrdU incorporation. Results are shown as the mean value7s.e.m. of one representative
experiment, and are expressed as relative values compared to untreated cells (control). Similar results were obtained in at least three other experiments.
*Pp0.01. **Pp0.001, ***Pp0.0001. J, proliferative effect of 10% FCS. The statistical test used is an unpaired t-test.
CCK2-R  c-Met   
-100
-500
100-
500-
LoVo LoVo BON BON
M+ M − + − + − + −
Figure 2 Expression of CCK2 receptor and HGF receptor (c-Met) in
BON cells. RT–PCR analysis of total RNA was performed with (þ)o r
without ( ) RT to rule out contamination of genomic DNA. PCR products
were visualised in ethidium bromide-stained 1.2% agarose gels, and showed
the expected sizes of 398bp (CCK2 receptor) and 395bp (c-Met),
respectively. LoVo cells were used as a positive control for CCK2 receptor
(Watson et al, 1998) and c-Met (Nabeshima et al, 1998). The results
shown are representative of three independent experiments. M: 100bp
DNA ladder molecular weight marker.
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Having established the proliferative responses to gastrin, HGF,
EGF and PACAP in BON cells, we performed transcript profiling
by cDNA microarray analysis in an effort to improve insight into
molecular mechanisms underlying these responses. A pilot study
where gene expression was analysed in BON cells treated with
gastrin for 2, 6, 16 or 24h demonstrated that the number of
differentially expressed genes was highest at 6h (data not shown).
We therefore used this time point for further microarray analysis.
We particularly focused on gastrin- and HGF-induced gene
expression for three reasons. First, there are reasons to believe
that gastrin plays a role as a regulator of carcinoid tumour growth
in vivo. Second, the novel finding that also HGF affects growth of
carcinoid tumour cells is interesting considering the central role
HGF plays as a growth regulator of other tumour cell types. Third,
gastrin and HGF represent growth factors acting through two
different main types of receptors: G-protein-coupled and tyrosin
kinase receptors, respectively.
Among the 2503 genes analysed, inference was performed for
2050 genes, where the number of observations was at least 3. Using
our two-step statistical procedure to identify differentially
expressed genes, we identified 95 genes to be regulated by gastrin,
of which 54 were up- and 41 were downregulated (Supplementary
Data). Furthermore, we identified 101 genes to be regulated by
HGF, of which 47 were up- and 54 downregulated (Supplementary
Data). These results were compared to the use of the moderated t-
tests using the Limma R package of Smyth (2004). The maximum
Limma P-value for the 95 potentially gastrin-regulated genes was
found to be 0.01 and the maximum q-value to be 0.17. For the 101
potentially HGF-regulated genes, the maximum Limma P-value
was 0.01 and the maximum q-value 0.12. We have previously
shown that the labelling method used in the present study results
in compressed microarray ratios, but quantitative RT–PCR
validation experiments performed here (Table 3) and previously
(Yadetie et al, 2003; Nørsett et al, 2004) have been able to confirm
the microarray data.
Based on information from the literature and from the
LocusLink and SwissProt databases, the genes were grouped
according to cellular processes in which they are likely to be
involved. Since we were interested in processes that are likely to
play a role in the context of cancer, we focused on cell
proliferation, apoptosis, cell adhesion, cell motility and oncogen-
esis. Even though many genes may be involved in more than one
process, each of the genes was grouped into only one category; this
regarded to be most relevant for the response studied here
(Table 2). Within these categories, we identified 27 genes that are
regulated by both gastrin and HGF (Table 2a), 30 that are only
regulated by gastrin (Table 2b), and finally, 25 that are only
regulated by HGF (Table 2c). The remaining 38 gastrin- and 49
HGF-responsive genes were regarded to participate in other
cellular processes, or to have unknown functions (all differentially
expressed genes are shown in Supplementary Data). Of the 95 and
101 gastrin- and HGF-responsive genes, similar proportions were
involved in cell proliferation (23–24%), cell motility/adhesion
(15–16%) and in apoptosis (4%). It was therefore interesting to
note that for the process oncogenesis, the proportion of gastrin-
responsive genes was twice as high (16%) as the proportion of
HGF-responsive genes (8%). This may indicate that the oncogenic
potential of gastrin in carcinoid cells is at least as high as that of
HGF.
Genes regulated by all growth factors
In order to identify common growth factor-responsive genes,
which may represent candidate genes of tumour growth regulation
in general, we compared gene expression induced by gastrin, HGF,
EGF and PACAP. In all, 12 genes were found to be significantly
regulated (Po0.05 from the t-test based on the linear mixed effects
model in the first step of our two-step procedure) by all the four
growth factors (Table 3), indicating that they may be universally
regulated during NE GI tumour cell proliferation. However, it is to
be noted that the concentration of PACAP (10nM) used in the gene
expression analysis only induced a weak proliferative response in
BON cells (Figure 1D). The common genes identified participate in
various cellular processes, as four of them encode proteins known
to be mediators of proliferation (EDN1, EGR3, ATF4 (activating
transcription factor 4), IL2RB), three encode proteins involved in
adhesion (CCR1, CDH11 (cadherin-11), LAMA5 (laminin, alpha
5)), two in metabolism (PCCA, PFKM), one in RNA splicing
(PPIG), and finally, two are involved in oncogenesis (CIN85,
PIM1).
Validation by real-time quantitative RT–PCR
It is well known that data from microarray analysis need to be
interpreted cautiously (Kothapalli et al, 2002). To validate the
microarray results in this study, we performed real-time quanti-
tative fluorescent RT–PCR analysis of seven selected genes using
the same RNA samples from gastrin- and HGF-treated cells as
those used in the microarray analysis. Concordant results were
found for all the four upregulated genes tested (ATF4, LAMR1
(laminin receptor 1), BTG1, RRM2) (Table 4), while one (IGFBP1)
out of three downregulated genes tested (EPS15, IGFBP1, PIM1)
was confirmed to be differentially expressed (Table 4). The serine/
threonine kinase PIM1 proto-oncogene was, by RT–PCR analysis,
shown to be slightly upregulated by gastrin, and markedly
upregulated by HGF. In prostate cancer, the expression of the
PIM1 protein has been shown to correlate with clinical outcome
(Dhanasekaran et al, 2001), and the novel detection of this proto-
oncogene in carcinoid tumour cells warrants further studies to
explore its role as a potential prognostic marker also in NE GI
tumours.
Our confirmatory rate of 71% underlines the need to verify
microarray data by other methods, but our verification results
seem to be in accordance with that of others (Kothapalli et al,
2002) and that previously shown by us (Nørsett et al, 2004; Yadetie
et al, 2003).
Table 1 Primer sequences of selected genes for confirmation studies
Gene PCR products (bp)
EPS15 S-50-CTG TCC CAA ACC CTT TAC A-30 130
AS-50 AGA ATC CCA TCC ATA TAT CCA-30
IGFBPI S-50-GGA GGA CGG TTA ACT TGT AT-30 130
AS-50-AAC AAC ATA TCC AGG TAC ATT-30
PIM1 S-50-GGA GAC CCC AGA TAG GAC-30 125
AS-50-GGA GAT AGG AAG CCA GAC TAC-30
RRM2 S-50-AGC AAG CGA TGG CAT AG-30 110
AS-50-GTA TGT TTT CCA TGG CAA TTT-30
ATF4 S-50-GGA GAC CCC AGA TAG GAC TC-30 110
AS-50-GAC TAC ACT GCT TAC GTT GCC-30
LAMR1 S-50-TGA AAT TCC TCC TTG GTC ACT-30 120
AS-50-CAT TTC CCG TGA ACA CCC-30
BTG S-50-CAA CTT TGC CAC AAT CAA TA-30 141
AS-50-CTT TCC TTG TAC TTA ATT GGG-30
GAPDH S-50-TCT GAC TTC AAC AGC GAC ACC-30 118
AS-50-TGT TGC TGT AGC CAA ATT CGT-30
PCR¼polymerase chain reaction; S¼sense; AS¼antisense.
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sTable 2 Genes significantly
a regulated by (a) both gastrin and HGF, (b) gastrin and not by HGF and (c) HGF and not by gastrin
Ratio
c
Gene symbol Gene name Accession
b Gastrin HGF
(a) Both gastrin and HGF
Cell proliferation
ATF4 Activating transcription factor 4 AA600217 1.63 1.46
CCNI Cyclin I AA434408 1.52 1.42
ANXA11 Annexin A11 AA465051 1.47 1.27
MCM3 Minichromosome maintenance deficient 3 AA455786 1.35 1.38
NP Nucleoside phosphorylase AA430382 1.29 1.30
STK12 Serine/threonine kinase 12 AA071486 1.25 1.28
IL2RB Interleukin 2 receptor, beta AA057156 0.48 0.46
GNRH1 Gonadotropin-releasing hormone 1 AA043996 0.55 0.57
EPS15 EGF receptor pathway substrate 15 AA490223 0.66 0.63
LOC51177 CK2-interacting protein 1 AA490216 0.76 0.75
SCYA16 Small inducible cytokine subfamily A (Cys–Cys), member 16 T58775 0.77 0.70
Apoptosis
BAK1 BCL2 antagonist/killer 1 H52673 1.26 1.29
HCLS1 Hematopoietic cell-specific Lyn substrate 1 AA424575 0.77 0.77
Cell adhesion/motility
LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein AA485353 1.54 1.45
MAP1B Microtubule-associated protein 1B AA219045 1.54 1.33
LAMR1 Laminin receptor 1 AA629897 1.49 1.41
MIG Monokine induced by gamma interferon AA131406 0.53 0.66
CCR1 Chemokine (C–C) motif receptor 1 AA036881 0.63 0.60
CDH11 Cadherin 11 AA136983 0.66 0.65
LAMA5 Laminin, alpha 5 AA459519 0.77 0.72
ITGAV Integrin, alpha V AA029934 0.77 0.78
Oncogenesis
MLF2 Myeloid leukemia factor 2 AA480835 1.30 1.40
CIN85 c-Cbl-interacting protein AA989257 1.31 1.26
LMO2 LIM domain only 2 AA464644 1.29 1.31
GSTT1 Gluatathione S-transferase theta 1 H99813 1.25 1.35
PIM1 Pim-1 oncogene AA453663 0.75 0.50
RAB18 RAB18, member RAS oncogene family AA156821 0.79 0.75
Gene symbol Gene name Accession
b Ratio
c
(b) Gastrin and not by HGF
Cell proliferation
RRM2 Ribonucleotide reductase M2 polypeptide AA187351 1.59
BTG1 B-cell translocation gene 1 N70463 1.57
IL-8 Interleukin 8 AA102526 1.46
EGR3 Early growth response 3 R39111 1.45
ERCC5 Excision repair crosscomplementing rodent repair deficiency, complementation group 5 N62586 1.44
MCM3 Minichromosome maintenance deficient 3 AA455786 1.35
FGF1 Fibroblast growth factor 1 (acidic) AA015793 1.30
ETR101 Immediate-early protein AA496359 1.27
RAD23A RAD23 (C. cervisiae) homolog A AA476274 1.26
CAMK2D Calcium/calmodulin-dependent protein kinase (camkinase) II delta AA283023 1.26
LIG3 Ligase III, DNA, ATP dependent AA149292 0.61
HDAC2 Histone deacetylase 2 AA127093 0.72
Apoptosis
PPARG Peroxisome proliferative-activated receptor, gamma A088517 1.3
LTBR Lymphotoxin beta receptor AA454646 0.67
Cell adhesion/motility
RCN2 Reticulocalbin 2 AA598676 1.36
SERPINA5 Serine (or cysteine) proteinase inhibitor, member 5 AA858026 1.28
CDH6 Cadherin 6 AA421819 1.25
SYK Spleen tyrosine kinase AA598572 0.63
IGFBP1 Insulin-like growth factor binding protein 1 AA233079 0.66
SCYA2 Small inducible cytokine A2 AA425102 0.71
MMP7 Matrix metalloproteinase 7 AA031513 0.78
Oncogenesis
HOXA1 Homeo box A1 AA173290 1.33
S100A3 S100 calcium-binding protein A3 AA055242 1.29
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sDISCUSSION
Growth factor-induced signalling impacts on many aspects of
tumour biology. The results of this study contribute to an
increased knowledge of molecular events underlying growth
factor-induced proliferation of human NE GI tumour cells, by
identifying a number of novel growth-responsive genes. Our study
also sheds new lights into the biology of NE GI tumours, and
provides candidate genes in the search for new therapeutic targets.
To the best of our knowledge, only a few of the growth factor-
responsive genes identified in this study have earlier been shown
to be regulated by the respective factors. However, the demonstra-
tion of differential expression of already known growth factor-
responsive genes confirms the reliability of our results. In a study
investigating the transcriptional response to HGF in mouse
embryo liver cells, HGF was found to regulate a number of
extracellular matrix proteins (Medico et al, 2001). Similar to the
findings in that study, we confirmed the upregulation of the gene
COL1A2 (collagen, type I, alpha), and the downregulation of
LAMA5 by HGF. Furthermore, gastrin was shown to upregulate the
expression of interleukin-8 (IL-8), which has earlier been identified
as a gastrin-regulated gene in rat gastric epithelial cells (Hiraoka
et al, 2001). IL-8 has been shown to contribute to human cancer
progression through its mitogenic, angiogenic and migratory
action (Xie, 2001). In accordance with a recently published study
performed using rat pheochromocytoma PC12 cells (Grumolato
et al, 2003), we identify LAMR1 as a PACAP-responsive gene.
Finally, tissue inhibitor of metalloproteinase 3 (TIMP3) is
recognised as an HGF-responsive gene, as previously shown by
Castagnino et al (1998).
Annotations of the genes reveal that the majority of the novel
gastrin- and HGF-responsive genes seem to participate in
processes relevant in the context of tumour biology. However, it
has to be noted that cancer-related genes were well represented on
EWSR1 Ewing sarcoma break point region 1 AA464184 1.29
UBE3A Ubiquitin protein ligase E3A N94099 1.29
SIAT4C Sialyltransferase 4C AA453898 1.25
CHC1L Chromosome condensation 1-like AA495766 0.66
LBC Lymphoid blast crisis oncogene AA156936 0.70
MEL Mel transforming oncogene AA064715 0.77
OS-9 Amplified in osteosarcoma AA03336 0.77
(c) HGF and not by gastrin
Cell proliferation
ELK4 ETS-domain protein (SRF accessory protein 1) H61758 1.55
MAT2A Methionine adenosyltransferase II, alpha T59286 1.53
MAPK4 Mitogen-activated protein kinase 4 AA401035 1.40
IGF2R Insulin-like growth factor 2 receptor T62547 1.32
PDGFRA PDGF receptor alpha polypeptide H23235 1.27
CDC6 CDC6 homolog H59203 1.26
GSK3B Glycogen synthase kinase 3 beta R93911 1.26
BDNF Brain-derived neurotrophic factor AA262988 0.66
TNFRSF11B TNF receptor superfamily, member 11 AA194983 0.67
JUND Jun D proto-oncogene AA418670 0.73
TSC22 TGF beta-stim protein TSC-22 AA664389 0.75
STATI2 STAT induced STAT inhibitor 2 AA137031 0.78
TOB1 Transducer of ERBB2,1 AA490213 0.79
Apoptosis
TIMP3 Tissue inhibitor of metalloproteinase 3 AA099153 0.55
BIRC1 Baculoviral IAP repeat-containing 1 AA621150 0.80
Cell adhesion/motility
ACTG2 Actin, gamma 2, smooth muscle, enteric T60048 1.52
COL1A2 Collagen, type I, alpha 2 AA490172 1.35
MYPT2 Myosin phosphatase, target subunit 2 AA463926 1.36
DSP Desmoplakin (DPI, DPII) H90899 1.30
PCDH1 Protocadherin 1 (cadherin-like 1) AA443557 1.27
CD164 CD164 antigen, sialomucin AA598561 0.55
SDC4 Syndecan-4 AA148736 0.72
CD58 CD58 antigen AA136359 0.75
Oncogenesis
WT1 Wilms tumor 1 AA130187 0.76
KIAA0203 KIAA0203 gene product AA047435 0.76
HGF¼hepatocyte growth factor.
aSignificantly (Pp0.05) differentially expressed genes with a microarray ratio o0.8 or 41.25 using the two-step procedure outlined in the
Materials and Methods section.
bGenBank accession number. Listed are genes with functions relevant in cancer biology. The remaining genes with other or unknown functions
are listed in Supplementary Data. The gastrin data are based on samples from two biological experiments, of which one sample was hybridised once, and the other twice. The
HGF data are based on samples from two biological experiments, which both were hybridised twice.
cMicroarray ratio (treated/untreated cells).
Table 2 (Continued)
Ratio
c
Gene symbol Gene name Accession
b Gastrin HGF
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proteins involved in cell proliferation were found to be regulated
by gastrin and/or HGF. Gastrin was shown to upregulate the
mRNA expression of the small M2 subunit of ribonucleotide
reductase (RRM2), a rate-limiting enzyme in DNA synthesis and
repair (Zhou and Yen, 2001). Several nonspecific inhibitors of
ribonucleotide reductase are in fact already in clinical use as
chemotherapeutic agents, and more recently, an antisense agent
targeting RRM2 has shown potent antitumour activity against a
variety of tumours (Lee et al, 2003). As far as we know, our study is
the first one to demonstrate that polypeptide growth factors may
affect the expression of RRM2, as also PACAP was shown to induce
an upregulation.
Gastrin, HGF and PACAP were all shown to upregulate the
expression of the highly conserved LAMR1 gene that plays a role in
cell adhesion. This is interesting as there seems to be a correlation
between the upregulation of LAMR1 in cancer cells, and their
invasive and metastatic phenotype (Menard et al, 1998). Further-
more, gastrin was shown to downregulate the expression of spleen
tyrosine kinase (SYK) gene. Reduced expression of this gene has
been shown to be associated with distant metastasis and poor
prognosis in breast cancer (Toyama et al, 2003), indicating that it
may be a potential tumour suppressor and antimetastasis gene.
Thus, downregulation of SYK may contribute to the assumed
tumorigenic potential of gastrin. As elevated serum levels of the
tumour-associated glycoprotein lectin, galactoside-binding, solu-
ble, 3 binding protein (LGALS3BP) (Table 2a) are often observed in
cancer patients, and have been proven to be of prognostic value
(Marchetti et al, 2002), the findings that both gastrin and HGF
upregulate the expression of LGALS3BP justify studies exploring
LGALS3BP expression in carcinoid tumour patients as well.
Gastrin and HGF affected the expression of several genes
encoding proteins thought to be involved in apoptosis (Table 2a–
c). As mentioned above, TIMP3 has earlier been recognised as an
HGF-responsive gene, and here we demonstrate a marked down-
regulation of this proapoptotic gene after treatment with HGF.
This is interesting as we know that loss of TIMP3 expression may
enhance the invasive potential of certain tumours (Castagnino
et al, 1998). Moreover, gastrin was shown to downregulate the
expression of lymphotoxin beta receptor (LTBR). Activation of this
receptor has been shown to induce apoptosis in some tumour cells
(Browning et al, 1996), and thus a downregulation of its expression
probably undermines its apoptotic effect.
It is noted that a considerably higher percentage of gastrin- than
HGF-regulated genes were found to encode proteins considered to
be involved in oncogenesis. Aberrant HGF/c-Met signalling has
been well documented in a variety of human cancers (Maulik et al,
2002), and our results strengthen the view that also the gastrin
signalling pathway could be involved in oncogenesis (Waldum
et al, 1995; Dockray et al, 2001). An abberant expression of the
homeo box A1 (HOXA1) gene is assumed to be the mechanism by
which autocrine stimulation with human growth factor may result
in oncogenic transformation, and it has recently been shown that
forced expression of this gene in human mammary epithelial cells
is sufficient for transformation of the cells (Zhang et al, 2003). Our
finding that gastrin upregulates the expression of the HOXA1 gene
indicates that this may be one mechanism by which gastrin could
play a role in oncogenesis. Another mechanism could be through
an upregulation of the mRNA of S100 calcium-binding protein A3
(S100A3), as this gene has been proposed to play a role in NE
tumorigenesis (Sta ˚lberg et al, 2001). Additional support to such a
view is the finding that gastrin downregulates the expression of the
chromosome condensation 1-like (CHC1L) gene. This gene has
recently been proposed to be a candidate gene for prostate
carcinogenesis (Latil et al, 2003).
Crosstalks between various growth factor systems are a well-
known phenomenon, and underline the complexity of tumour
growth control. Gastrin has previously been shown to enhance the
expression of both HGF (Konturek et al, 2003) and heparin-
binding EGF-like growth factor (Dockray et al, 2001). In the
present study, links to the IGF system were observed. This is of
particular interest since IGF-1 is known to act as an autocrine
growth factor of BON cells (von Wichert et al, 2000). Gastrin was
shown to downregulate the expression of the IGFBP-1 (Tables 2b
and 4). IGFBP-1 is known to neutralise the actions of IGF-1, but in
addition, it exerts independent actions as it inhibits breast cancer
cell motility and growth by itself (Zhang and Yee, 2002). In fact, in
Table 3 Genes significantly
a regulated by all growth factors
Gene symbol Gene name Accession
b
Upregulated
EDN1 Endothelin 1 H11003
PCCA Propionyl coenzyme A carboxylase,
alpha polypeptide
AA608575
PPIG Peptidyl-prolyl isomerase G AA458502
CIN85 c-Cbl-interacting protein AA989257
EGR3 Early growth response 3 R39111
ATF4 Activating transcription factor 4 AA600217
Downregulated
IL2RB Interleukin 2 receptor, beta AA057156
CCR1 Chemokine (C–C motif) receptor 1 AA036881
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) AA136983
PFKM Phosphofructokinase, muscle AA099169
PIM1 Pim-1 oncogene AA453663
LAMA5 Laminin, alpha 5 AA459519
aGenes significantly (Po0.05) down- or upregulated by gastrin, HGF, EGF and
PACAP using the first step of the two-step procedure outlined in the Materials and
Methods section.
bGenBank accession number. The gastrin data are based on
samples from two biological experiments, of which one sample was hybridised once,
and the other twice. The HGF data are based on samples from two biological
experiments, which both were hybridised twice.
Table 4 Verification of microarray data by quantitative RT–PCR analysis
Gene Treatment PCR ratio
a Microarray ratio
b
ATF4 Gastrin 2.1 1.6
HGF 1.5 1.5
BTG1 Gastrin 1.2 1.5
HGF 1.2 1.2
RRM2 Gastrin 1.2 1.7
HGF 1.0 1.2
LAMR1 Gastrin 1.3 1.6
HGF 1.1 1.3
IGFBPI Gastrin 0.9 0.7
HGF 0.8 0.8
EPS15 Gastrin 1.0 0.7
HGF NA 0.6
PIM1 Gastrin 1.8 0.8
HGF 1.1 0.6
RT–PCR¼reverse transcriptase–polymerase chain reaction; HGF¼hepatocyte
growth factor; NA; not analysed.
aRNA transcript level in arbitrary units was
standardised by the level of GAPDH, and expressed as fold change in treated relative
to untreated cells. RT–PCR analysis was performed with the same total RNA as used
in the microarray experiments. PCR ratios calculated from analysis of one biological
sample with either gastrin or HGF are shown.
bCorresponding microarray ratio for
the same biological sample.
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sbreast cancer several strategies are currently being exploited using
the IGF system as a biological target (Yee, 2002). Thus, a
downregulation of IGFBP1 by gastrin may be one mechanism
whereby gastrin promotes tumour growth and invasion. Another
link to the IGF system was also noted, as HGF was shown to
upregulate the expression of the IGF receptor 2 (IGFR2). Our data
also indicate connections to other growth factor systems, as gastrin
was shown to upregulate the expression of acidic fibroblast growth
factor 1 (FGF1), while both gastrin and HGF were shown to
decrease the expression of EGF receptor pathway substrate 15
(EPS15). HGF also increased the expression of PDGF receptor
alpha polypeptide (PDGFRA), while PACAP was shown to
upregulate the expression of the HGF-receptor c-Met.
PACAP was shown to induce a rather strong upregulation of IL-
8. This is similar to gastrin, which also acts through a G-protein-
coupled receptor. In contrast, no regulation was seen after
treatment with the tyrosine kinase-acting ligands HGF and EGF.
A similar pattern was observed with regard to RRM2 expression, as
the tyrosine kinase receptor-activating ligands HGF and EGF did
not affect the expression of RRM2, while gastrin and PACAP
upregulated RRM2 RNA levels.
One objective of this study was to identify genes that were
regulated by all four growth factors, since such genes could
possibly be regarded as universally regulated during tumour cell
proliferation, and thus assumed to be of particular interest in the
search for new drug targets. In all, 12 genes fulfilled the criteria,
indicating that these genes may play a central role in NE GI
tumour cell proliferation. Gastrin, HGF, EGF and PACAP were all
shown to increase strongly the mRNA of ATF4, a member of the
ATF/CREB family of mammalian transcription factors found to be
expressed in all tissues examined so far (Hai and Hartman, 2002).
Heregulin, a combinatorial ligand for EGFR 3 and 4, has earlier
been found to upregulate ATF4 mRNA as well as ATF4 protein in
human cancer cells (Talukder et al, 2000). Together, this indicates
that ATF4 could play a central role in the mechanisms of tumour
growth regulation in general.
Another interesting feature observed with all four growth factors
was marked downregulation of the beta chain of the interleukin 2
receptor (IL2RB). IL2 is known to inhibit proliferation and growth
of various cancer cells (Casana et al, 2002), and thus a
downregulation of a subunit of its receptor may be one additional
mechanism whereby growth factors in general promote growth. All
four growth factors were shown to downregulate the expression of
CDH11. This has previously been shown to be the case also after
treatment with transforming growth factor-a (Zhou and Skalli,
2000). As CDH11-overexpressing osteosarcoma cells have been
found to exhibit a marked reduction in their ability to form
pulmonary metastasis (Kashima et al, 2003), a downregulation of
CDH11 may be one mechanism by which growth factors contribute
to tumour progression. Finally, all growth factors were shown to
downregulate the expression of LAMA5, which is interesting as a
reduced level of LAMA5 has been shown to be associated with an
increased tendency to develop lymph node metastasis in non-
small-cell lung cancer (Akashi et al, 2001).
Our data showing that all four growth factors analysed may
induce the expression of genes known to impact on many aspects
of cancer indicate that these factors may play an important role in
the establishment, growth and metastases of NE GI tumours, and
that targeting their receptors, signalling pathways or secondary
gene expression may be a possible way to stop or delay growth of
such tumours. As mentioned above, targeting the EGF system has
already become an established treatment modality in some types of
tumours (Sridhar et al, 2003; Ranson, 2004), and has been shown
to inhibit growth of NE GI tumour cells (Ho ¨pfner et al, 2003).
Similarly, the pivotal role that HGF seems to play in cancer has led
to the preclinical development of many types of targeting drugs,
including antagonists, which compete with binding to the receptor,
antibodies, which block the receptor, small-compound tyrosin
kinase inhibitors, or other strategies that target downstream
signals or secondary gene expression (Jiang et al, 2005).
In light of the fact that tumour growth in vivo is most often
influenced by many different growth factors, either in a paracrine,
autocrine or systemic manner, our identification of genes that are
regulated by more than one factor in NE GI tumour cells may be of
particular interest with regard to intervention of NE tumour
disease. In addition, the demonstration in this paper of crosstalks
between various growth factor systems strengthens the view
that it probably will be more efficient to target more than one
growth systems, as more recently has been shown in NE medullary
thyroid cancer preclinical models (Ezzat et al, 2005). Our
identification of ATF4 as a common inducible growth factor gene
may indicate that silencing of this gene, for example, by use of
siRNAs or antisense technology, may be an interesting approach to
further study. Furthermore, the demonstration that gastrin and
PACAP, similar to tumour microenvironment factors such as
hypoxia, acidosis and nitric oxide (Xie, 2001), regulate IL-8
expression underline the need to further investigate the use of IL-
8-neutralising antibodies, IL-8 receptor blockers or IL-8 gene
silencing approaches in the treatment of NE GI tumours. More-
over, LAMR1, also known as ribosomal protein SA, turns out to be
an interesting candidate for further studies as both gastrin and
HGF were shown to upregulate its expression. To the best of our
knowledge, our study is the first to report LAMR1 expression in
NE tumour cells.
In conclusion, by identifying a number of growth factor-
responsive genes in human NE GI tumour cells, we have shed new
light into the molecular mechanisms involved in growth control of
these cells. Such knowledge is essential in order to design studies
aimed to evaluate functional aspects of candidate genes. Although
caution is advisable in the interpretation of microarray expression
data, we believe that our results provide suggestions for further
studies in the effort to identify new therapeutic targets as well as
new markers of NE GI tumours.
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